CXCL12 and neoplasm: However, anti-CXCR4 ADC may also target various cell types infiltrating the tumour microenvironment recruited through the CXCL12/CXCR4 pathway and that support tumour growth, such as bone marrow-derived mesenchymal, vascular and myeloid cells9.